Search results
Results from the WOW.Com Content Network
Lung Cancer is a peer-reviewed medical journal published by Elsevier originally published on behalf of the International Association for the Study of Lung Cancer (until 2006). As of 2015, it is published on behalf of the International Lung Cancer Consortium , the European Thoracic Oncology Platform , and the British Thoracic Oncology Group . [ 1 ]
Clinical Lung Cancer is a peer-reviewed medical journal that has been published by Elsevier since 2011. It was established by the CIG Media Group in 1999. History
Original file (1,129 × 883 pixels, file size: 7 KB, MIME type: application/pdf) This is a file from the Wikimedia Commons . Information from its description page there is shown below.
Lung cancer is the most diagnosed and deadliest cancer worldwide, with 2.2 million cases in 2020 resulting in 1.8 million deaths. [3] Lung cancer is rare in those younger than 40; the average age at diagnosis is 70 years, and the average age at death 72. [2] Incidence and outcomes vary widely across the world, depending on patterns of tobacco use.
In the fifty years leading up to the Wynder and Graham study, lung cancer was observed to have risen dramatically and disproportionately in comparison to other cancers. From the 1920s to 1950, the year of the study's publication, deaths from lung cancer had quadrupled so now it was the leading cancer found in men. [8]
Small cell lung cancer is often treated as a systematic disease due to its tendency for early dissemination, [4] thus, instead of the traditional TNM staging system, the Veterans' Administration Lung Study Group (VALSG) introduced a simplified 2-stage system in the 1950s to divide small cell lung cancer into limited stage and extensive stage. [7]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Chemotherapy for NSCLC usually includes combination of two drugs (chemotherapy doublet), with one of the agents is cisplatin or carboplatin. In 2002, Schiller at al. published in the New England Journal of Medicine, a study that compared four chemotherapy regimens for advanced NSCLC, cisplatin and paclitaxel, cisplatin and gemcitabine, cisplatin and docetaxel, and carboplatin and paclitaxel. [14]